title: Respiratory syncytial virus therapy and prophylaxis: have we finally turned the corner?
authors.forename: R G
authors.initials: RG
authors.lastname: Hegele
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D000069455:Palivizumab; D011725:Pyridines / Q000627:therapeutic use*; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D022261:Respiratory Syncytial Virus Vaccines / Q000009:adverse effects / Q000627:therapeutic use; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D014760:Viral Fusion Proteins / Q000037:antagonists & inhibitors
chemical_list: C528854:2-(6-((2-(3-hydroxypropyl)-5-methylphenylamino)methyl)-2-(3-morpholin-4-ylpropylamino)benzoimidazol-1-ylmethyl)-6-methylpyridin-3-ol; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D001562:Benzimidazoles; D016756:Immunoglobulins, Intravenous; D011725:Pyridines; D022261:Respiratory Syncytial Virus Vaccines; D014760:Viral Fusion Proteins; D012254:Ribavirin; D000069455:Palivizumab